Valuation: Corcept Therapeutics Incorporated

Market Cap 9.29B 8.33B 7.66B 6.94B 12.98B 882B 13.22B 91.18B 36.64B 464B 34.87B 34.12B 1,464B P/E 2026 *
39.8x
P/E 2027 * 19.7x
Enterprise Value 9.29B 8.33B 7.66B 6.94B 12.98B 882B 13.22B 91.18B 36.64B 464B 34.87B 34.12B 1,464B EV / Sales 2026 *
8.11x
EV / Sales 2027 * 5.54x
Free-Float
65.89%
Yield 2026 *
-
Yield 2027 * -
1 day-5.62%
1 week-24.54%
Current month-29.60%
1 month-29.30%
3 months-12.73%
6 months+74.11%
Current year+133.10%
1 week 80.28
Extreme 80.28
91.78
1 month 80.28
Extreme 80.28
122.81
Current year 28.66
Extreme 28.6601
126.38
1 year 28.66
Extreme 28.6601
126.38
3 years 20.84
Extreme 20.84
126.38
5 years 15.82
Extreme 15.825
126.38
10 years 6.7
Extreme 6.7
126.38
Manager TitleAgeSince
Chief Executive Officer 68 31/12/1998
Director of Finance/CFO 49 28/02/2021
Chief Tech/Sci/R&D Officer 48 31/01/2024
Director TitleAgeSince
Director/Board Member 68 31/12/1998
Chairman 82 31/12/1998
Director/Board Member 71 30/06/2004
Date Insider Type Main position Quantity % Market Cap. Importance
15/10/26 Sell

Chairman

-10,000 0.0093%
02/10/26 Exercice

See Remarks

73,761 0.0682%
02/10/26 Exercice

Chief Technology Officer

27,570 0.0255%
Change 5-day change 1-year change 3-year change Capi.($)
-5.62%-24.54%+12.59%+197.58% 9.29B
+3.19%+8.48%+74.25%+153.03% 1,224B
-0.73%+2.09%+46.41%+87.64% 662B
+1.41%+3.40%+30.98%+112.26% 514B
+0.42%+2.88%+54.92%+69.67% 388B
+2.18%+1.55%+72.70%+45.42% 361B
+1.12%+3.80%+35.82%+59.72% 302B
+6.96%+7.55%+11.15%+37.89% 271B
+1.15%+4.19%+59.72%+78.16% 249B
+3.06%+8.58%+44.03%+122.76% 205B
Average +0.97%+0.33%+44.26%+96.41% 418.61B
Weighted average by Cap. +1.18%+2.99%+53.26%+100.64%

Financials

2026 *2027 *
Net sales 1.15B 1.03B 945M 856M 1.6B 109B 1.63B 11.25B 4.52B 57.23B 4.3B 4.21B 181B 1.68B 1.5B 1.38B 1.25B 2.34B 159B 2.38B 16.45B 6.61B 83.69B 6.29B 6.16B 264B
Net income 242M 216M 199M 180M 338M 22.93B 344M 2.37B 952M 12.06B 906M 887M 38.05B 568M 510M 469M 424M 794M 53.97B 809M 5.58B 2.24B 28.38B 2.13B 2.09B 89.54B
Net Debt - -
Projected Income Statement - Annual - Corcept Therapeutics Incorporated
Logo Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. It is also conducting advanced clinical trials in patients with solid tumors, Amyotrophic Lateral Sclerosis (ALS) and liver disease. It operates through the discovery, development and commercialization of the pharmaceutical products segment. It sells Korlym and a generic version of Korlym in the United States using sales representatives to call on physicians caring for patients with hypercortisolism (Cushing’s syndrome). The Company's portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. It sells and distributes Lifyorli in the United States. It is developing its proprietary, selective cortisol modulator, relacorilant, as a treatment for patients with hypercortisolism.
Employees
730
Date Price Change Volume
30/10/26 US$81.12 -5.62% 1,425,908
29/10/26 US$85.95 -0.38% 1,185,785
28/10/26 US$86.28 -1.50% 1,048,071
27/10/26 US$87.59 +0.53% 925,519
26/10/26 US$87.13 +1.47% 1,872,204
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Corcept Therapeutics Incorporated
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
81.12USD
Average target price
141.00USD
Spread / Average Target
+73.82%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Corcept Therapeutics Incorporated
  1. Stock Market
  2. Stocks
  3. CORT Stock